MicroPort Medical and Tinavi Form Strategic Alliance to Target Global Orthopedic 'Robotics + Implants' Integrated Market

Stock trading depends onGolden Kirin Analyst Research Report, authoritative, professional, timely, and comprehensive, helping you uncover potential thematic opportunities!

(Source: Pao Finance)

On the evening of July 15, MicroPort Scientific Corporation (00853.HK) issued a voluntary announcement that its subsidiary hasTINAVI(688277.SH) signed a letter of intent, whereby TINAVI intends to acquire a controlling stake in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. (the “Target Company”) to gain control over MicroPort’s overseas orthopedic business assets. The transaction will be conducted through share-based payment. The consummation of the transaction remains subject to the signing and effectiveness of definitive agreements, as well as the completion of other necessary approval procedures.

This move marks the overseas first-tier orthopedic consumables enterprises and orthopedic surgeryRobotThe alliance between industry leaders aims to accelerate competition in the overseas integrated orthopedics market through deep strategic binding.

MicroPort’s overseas orthopedics business has been deeply engaged in the orthopedic field for over two decades, establishing itself as one of the leading international joint replacement companies. It primarily conducts orthopedic consumables business—mainly knee and hip implant products—in major overseas markets such as the United States, Japan, and Europe, and possesses mature and extensive marketing channels abroad. To date, MicroPort’s overseas orthopedics business spans more than 70 countries and regions worldwide. Its representative product, the InnerAxis Knee System, boasts over 20 years of clinical application history, with cumulative global implants exceeding one million cases, demonstrating a solid foundation in clinical practice and broad market recognition.

Beijing TINAVI Medical Technologies Co., Ltd. is a company listed on the STAR Market, dedicated to the independent innovation, scaled manufacturing, specialized marketing, and high-quality clinical application of orthopedic surgical robots and related technologies. As the first Chinese manufacturer of orthopedic surgical robots to receive certification from the China Food and Drug Administration (CFDA), TINAVI pioneered the global launch of a surgical robot platform covering three major orthopedic fields—spine, joint, and trauma—thereby achieving multi-indication coverage with a single system. The company’s products rank first in the domestic market in terms of hospital coverage and surgical application volume. By the end of the first quarter of 2026, the clinical application of its core product, the Tiandi Series orthopedic surgical robots, had extended to more than 200 medical institutions across 31 provinces, autonomous regions, and municipalities in China, with the number of surgeries performed exceeding 160,000 cases.

Industry insiders analyze that MicroPort’s overseas orthopedic business and TINAVI have each deeply cultivated their respective tracks in the two major orthopedic surgical fields—hip and knee joint consumables, and surgical robots. Leveraging their respective strengths, profound industry understanding, and extensive experience, they will form a powerful force in the field of robotic-assisted orthopedic surgery through strategic collaboration, amidst the global trend toward integrated medical devices and consumables.

Embracing the “Robot + Consumables” Integration Trend: Consolidation as the Key to Breakthrough Development

In recent years, the competitive landscape of the global orthopedics industry has undergone profound changes, with the deep integration of “robotics + implants” becoming the mainstream competitive paradigm overseas. Leading companies in the industry generally adopt an efficient strategy of “leveraging consumables distribution channels to introduce robotic systems, and then using robotics to drive repeat purchases of consumables,” thereby achieving high growth in their consumables business and actively expanding in-hospital sales.

Successful cases in the market have also confirmed this development trend. Prior to 2013, Stryker’s market position in the field of knee arthroplasty was relatively weak, and it faced pressure from losing market share. In September 2013, Stryker announced the acquisition of Mako Surgical, with the transaction completed in December of the same year. At the time of the acquisition, Mako’s annual revenue for 2012 was approximately $103 million. Following the acquisition, Stryker deeply integrated the Mako surgical robot with its own joint implant business, achieving a closed-loop business model of “devices + consumables.” This strategy yielded significant results: Stryker’s overall sales grew from $9 billion in 2013 to $14.9 billion in 2019; sales in the orthopedics segment increased from $3.9 billion in 2013 to $5.3 billion in 2019. According to ORTHOWORLD statistics, over the past decade, Stryker has captured nearly 6.5 percentage points of cumulative market share in the joint replacement market, with the vast majority of this growth attributed to the Mako surgical robot platform. As of 2024, 60% of knee arthroplasty procedures and 34% of hip arthroplasty procedures in the United States were performed using the Mako system.

The widespread adoption of surgical robots has not only driven equipment sales but also significantly expanded the market potential for related prostheses and consumables. Leveraging preoperative personalized planning, precise navigation and positioning, and robotic arm support systems, surgical robots can substantially enhance the accuracy of prosthesis implantation and optimize surgical outcomes. Leading international orthopedic consumable manufacturers have generally established a closed-loop usage model that integrates implantable prostheses with surgical robots. This strategy effectively drives sustained growth in prosthesis sales through the placement and sale of surgical robotic systems. For instance, in the second quarter of 2025, Stryker reported a 6.3% increase in knee implant sales and an 8.9% increase in hip implant sales, both benefiting from the rising volume of Mako robotic-assisted surgeries. On a broader scale, the global market size for orthopedic surgical robots reached $6.83 billion in 2025, representing a 24.7% year-over-year growth from 2024. It is projected to exceed $21.5 billion by 2030, maintaining a compound annual growth rate (CAGR) of approximately 25.9%. More importantly, the proliferation of surgical robots continues to expand the overall implant market: total global orthopedic market sales reached $64.9 billion in 2025, a 4.9% year-over-year increase, while the joint reconstruction device market continued its steady expansion with a CAGR of over 5%.

The aforementioned industry trends and development directions will unlock substantial growth opportunities for the overseas orthopedic business of MicroPort and its collaboration with TINAVI.

MicroPort and TINAVI Join Forces to Compete in the Overseas Orthopedic Robotic Surgery Market

MicroPort’s overseas orthopedic business has developed products with strong global competitiveness by focusing on the research and development of high-quality innovative hip and knee joint solutions, including the Profemur® series femoral stems and the Evolution® Medial Pivot knee system. Its flagship product, the Medial Pivot knee, boasts over 20 years of clinical application history, with more than one million implants performed worldwide, demonstrating a solid foundation in clinical practice and broad market recognition. The excellent performance of the Medial Pivot knee has earned the highest rating from ODEP (Orthopaedic Data Evaluation Panel), a globally authoritative orthopedic assessment organization, marking the first time a Chinese company has received this honor. In terms of clinical validation, a long-term follow-up study published in 2017 in the medical journal *The Knee* included 325 patients who underwent a total of 347 total knee arthroplasties using the target company’s ADVANCE Medial Pivot knee system, with an average follow-up period of 15.2 years. The results showed that, with revision surgery as the endpoint, the cumulative survival rate of the Medial Pivot prosthesis was 98.8% at 17 years post-operation, and patient satisfaction reached 95%.

In the consumables segment, leveraging its leading-edge joint prosthesis product line, the orthopedics business boasts significant advantages in terms of deep expertise and a strong market foundation for the integrated development of the robotic orthopedic surgery market. This can effectively facilitate the adoption of TINAVI’s surgical robots in hospitals, thereby driving overseas sales of orthopedic consumables.

TINAVI boasts profound expertise and a leading advantage in the field of orthopedic surgical robots. By exporting clinically validated pathways from China, it can lower the procurement threshold for overseas hospitals, thereby facilitating smoother and faster hospital adoption through subsequent synergies in overseas orthopedic operations. As the first Chinese enterprise to participate in the formulation of international standards for the performance and safety of surgical robots, TINAVI leverages its domestic accumulation of 160,000 surgical cases and 5G remote surgery experience (such as through the National Orthopedic Robot Alliance project) to provide overseas customers with bundled “equipment + technical service” solutions. In August 2024, TINAVI’s orthopedic surgical navigation and positioning system and its associated toolkits obtained EU CE certification, establishing the regulatory foundation for entering European and American markets and laying the groundwork for competing in the global market.

According to the latest research published in the internationally renowned orthopedic clinical journal Journal of Orthopaedic Surgery and Research, analytical knee reconstruction based on the application of the TINAVI Tianji orthopedic surgical robot can significantly increase overall patient satisfaction to 97.6%, achieving a zero dissatisfaction rate. This is far higher than the industry norm where patient satisfaction with traditional manual TKA surgery has long remained at 80%. Moreover, the Forgotten Joint Score (FJS-12) reached as high as 78.0, significantly outperforming the 73.3 of the conventional robotic group and the 67.4 of the traditional surgery group.

The integrated powerhouse formed by MicroPort’s “performance-leading orthopedic implants” and TINAVI’s “state-of-the-art surgical robotic systems” will possess exceptional international competitiveness. The collaboration between MicroPort’s overseas orthopedic business and TINAVI represents a profound synergy between a globally leading consumables pipeline and cutting-edge surgical robotics technology. Evolving from single-point breakthroughs to a closed-loop ecosystem, both parties bring substantial strength in mutual empowerment across technological and market dimensions, inevitably unleashing growth momentum where “1+1>2.”

In the future, this alliance—forged by “orthopedic implants with leading performance” and “state-of-the-art surgical robots”—is poised to reshape the competitive landscape of the global orthopedic market as a disruptive force, delivering more precise and intelligent life-enhancing benefits to millions of patients worldwide.